Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 25, 2021

SGLT2 Inhibitors Plus GLP-1 Receptor Agonists Yield Benefits Across a Range of CV Outcomes



Additional Info

Disclosure statements are available on the authors' profiles:

Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Circulation 2021 Nov 14;[EPub Ahead of Print], CSP Lam, C Ramasundarahettige, KRH Branch, N Sattar, J Rosenstock, R Pratley, S Del Prato, RD Lopes, E Niemoeller, NS Khurmi, S Baek, HC Gerstein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading